Cabaletta Bio

Edit info

Founded: 2017

Location: Philadelphia, PA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Mucosal pemphigus vulgaris

Drug types: RAR, IMM, DRM, MUS, NEU, GEN, NPH

Lead product: DSG3-CAART

Funding: $100M stock May 2023; $75M IPO Oct 2019; $50M B Jan 2019; $38M Nov 2018

cabalettabio.com

linkedin.com

job board

Business:

Chimeric Auto Antibody Receptors

Drug notes:

MuSK-CAART Clin1 myasthenia gravis; PLA2R-CAART Clin0 membranous nephropathy; CABA-201 3 efforts Clin0 SLE, undisclosed; DSG3/1-CAART RD mucocutaneous pemphigus vulgaris

About:

Cabaletta Bio is developing T cell therapies for patients with B cell-mediated autoimmune diseases. Engineered T cell therapy takes advantage of T cell’s natural cell-killing capabilities and redirects their specificity to disease-causing cells by inserting a gene encoding a specific receptor. Known as chimeric antigen receptor (CAR) T cells, this approach has shown much success in cancer treatment. Cabaletta is encompassing CAR T cells for Autoimmunity (CARTA) which they hope to apply to many B cell-mediated autoimmune diseases. Cabaletta’s lead candidate in preclinical stages, CABA-201, is a fully human CD19 CARTA approach which has the potential to eliminate disease-causing B cells and allow for healthy B cell repopulation.